Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 18:11:571553.
doi: 10.3389/fmicb.2020.571553. eCollection 2020.

Small Non-coding RNAs: Do They Encode Answers for Controlling SARS-CoV-2 in the Future?

Pallabi Bhattacharyya  1 , Subhas C Biswas  1
Affiliations
Review

Small Non-coding RNAs: Do They Encode Answers for Controlling SARS-CoV-2 in the Future?

Pallabi Bhattacharyya et al. Front Microbiol. .

Abstract

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus responsible for the current COVID-19 (coronavirus disease 2019) pandemic, which has hit the world since December 2019. It has spread to about 216 countries worldwide, affecting more than 21.7 million people so far. Although clinical trials of a number of promising antiviral drugs and vaccines against COVID-19 are underway, it is hard to predict how successful these drug- or vaccine-based therapeutics are eventually going to be in combating COVID-19 because most of such therapeutic strategies have failed against human coronaviruses such as SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus) responsible for similar pandemics in the past. In that context, we would like to bring to scientific attention another group of endogenous regulatory molecules, the small non-coding RNAs, especially the microRNAs, which are found to regulate critical cellular pathways in a number of disease conditions, including RNA viral infections. This review will focus on understanding the effect of altered microRNA expression during coronavirus-mediated infections and how it may provide clues for further exploring the pathogenesis of SARS-CoV-2, with a view of developing RNAi-based therapeutics and biomarkers against COVID-19.

Keywords: COVID-19; MERS-CoV; RNA viruses; SARS-CoV; SARS-CoV-2; coronaviruses; microRNAs; non-coding RNAs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abbott T. R., Dhamdhere G., Liu Y., Lin X., Goudy L., Zeng L., et al. (2020). Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell 181 865.e12–876.e12. 10.1016/j.cell.2020.04.020 - DOI - PMC - PubMed
    1. Andersen K. G., Rambaut A., Lipkin W. I., Holmes E. C., Garry R. F. (2020). The proximal origin of SARS-CoV-2. Nat. Med. 26 450–452. 10.1038/s41591-020-0820-9 - DOI - PMC - PubMed
    1. Baumann V., Winkler J. (2014). miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Fut. Med. Chem. 6 1967–1984. 10.4155/fmc.14.116 - DOI - PMC - PubMed
    1. Bazzoni F., Rossato M., Fabbri M., Gaudiosi D., Mirolo M., Mori L., et al. (2009). Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc. Natl. Acad. Sci. U.S.A. 106 5282–5287. 10.1073/pnas.0810909106 - DOI - PMC - PubMed
    1. Bonneau E., Neveu B., Kostantin E., Tsongalis G. J., De Guire V. (2019). How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. Electr. J. Int. Fed. Clin. Chem. Lab. Med. 30 114–127. - PMC - PubMed